UY30399A1 - Uso de antagonistas de cgrp (a), sus enantinmeros, diasternmeros, mezclas y sales farmaccuticamente aceptables para preparar medicamentos, y composiciones que los contienen" - Google Patents

Uso de antagonistas de cgrp (a), sus enantinmeros, diasternmeros, mezclas y sales farmaccuticamente aceptables para preparar medicamentos, y composiciones que los contienen"

Info

Publication number
UY30399A1
UY30399A1 UY30399A UY30399A UY30399A1 UY 30399 A1 UY30399 A1 UY 30399A1 UY 30399 A UY30399 A UY 30399A UY 30399 A UY30399 A UY 30399A UY 30399 A1 UY30399 A1 UY 30399A1
Authority
UY
Uruguay
Prior art keywords
enantinmeros
diasternmeros
mixtures
compositions
contain
Prior art date
Application number
UY30399A
Other languages
English (en)
Inventor
Gerhard Schaenzle
Stephan Georg Mueller
Thierry Bouyssou
Kirsten Arndt
Henri Doods
Klaus Rudolf
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37101671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY30399(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of UY30399A1 publication Critical patent/UY30399A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invencion se refiere a un método para prevenir y tratar el dolor visceral y los trastornos gastrointestinales tales como trastornos funcionales del intestino y enfermedades inflamatorias del intestino mediante el uso de cantidades eficaces de un compuesto que actua como antagonista de CGRP.
UY30399A 2006-06-08 2007-06-07 Uso de antagonistas de cgrp (a), sus enantinmeros, diasternmeros, mezclas y sales farmaccuticamente aceptables para preparar medicamentos, y composiciones que los contienen" UY30399A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06011787 2006-06-08

Publications (1)

Publication Number Publication Date
UY30399A1 true UY30399A1 (es) 2008-01-31

Family

ID=37101671

Family Applications (2)

Application Number Title Priority Date Filing Date
UY30398A UY30398A1 (es) 2006-06-08 2007-06-07 " uso de antagonistas de cgrp (a), sus enantinmeros, diasternmeros, mezclas y sales farmaccuticamente aceptables para preparar medicamentos, y composiciones que los contienen"
UY30399A UY30399A1 (es) 2006-06-08 2007-06-07 Uso de antagonistas de cgrp (a), sus enantinmeros, diasternmeros, mezclas y sales farmaccuticamente aceptables para preparar medicamentos, y composiciones que los contienen"

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UY30398A UY30398A1 (es) 2006-06-08 2007-06-07 " uso de antagonistas de cgrp (a), sus enantinmeros, diasternmeros, mezclas y sales farmaccuticamente aceptables para preparar medicamentos, y composiciones que los contienen"

Country Status (19)

Country Link
US (2) US7807666B2 (es)
EP (2) EP2029234A1 (es)
JP (2) JP2009539799A (es)
KR (1) KR20090021214A (es)
CN (1) CN101500653A (es)
AR (2) AR061271A1 (es)
AU (1) AU2007255395A1 (es)
BR (1) BRPI0712492A2 (es)
CA (2) CA2654048A1 (es)
CL (2) CL2007001662A1 (es)
EA (1) EA200802381A1 (es)
EC (1) ECSP089025A (es)
IL (1) IL195712A0 (es)
MX (1) MX2008015562A (es)
NO (1) NO20085051L (es)
PE (2) PE20080370A1 (es)
TW (2) TW200815010A (es)
UY (2) UY30398A1 (es)
WO (2) WO2007141284A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080370A1 (es) * 2006-06-08 2008-06-13 Boehringer Ingelheim Int Derivados de quinazolinona como antagonistas de cgrp
WO2010070023A2 (en) * 2008-12-19 2010-06-24 Boehringer Ingelheim International Gmbh Formulations
FR2963738B1 (fr) * 2010-08-10 2012-09-28 Assist Publ Hopitaux De Paris Compose destine au traitement des douleurs abdominales fonctionnelles
EP2709662B1 (en) 2011-05-20 2019-07-31 AlderBio Holdings LLC Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
PL2710039T3 (pl) 2011-05-20 2019-07-31 Alderbio Holdings Llc Kompozycje przeciwko CGRP i ich zastosowanie
CN103702685B (zh) 2011-05-20 2017-12-15 奥尔德生物控股有限责任公司 抗cgrp抗体和抗体片段用于在有需要的受试者、尤其是偏头痛患者中预防或抑制畏光或厌光的用途
TWI636041B (zh) * 2015-08-12 2018-09-21 美國禮來大藥廠 Ｃｇｒｐ受體拮抗劑
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
EP3366286A1 (en) 2017-02-22 2018-08-29 Johannes Keller Compounds for treating sepsis
JP2022516956A (ja) 2019-01-08 2022-03-03 ハー・ルンドベック・アクチエゼルスカベット 抗ｃｇｒｐ抗体を用いた頭痛の急性治療及び迅速治療

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5291960A (en) * 1992-11-30 1994-03-08 Ford Motor Company Hybrid electric vehicle regenerative braking energy recovery system
DE10250080A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10250082A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7595312B2 (en) * 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
WO2005041757A2 (en) * 2003-10-29 2005-05-12 University Of Rochester Detection of neuropeptides associated with pelvic pain disorders and uses thereof
DE102004015723A1 (de) * 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004019492A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004063755A1 (de) * 2004-12-29 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs
DE102004063753A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
DE102004063752A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
EP1770091A1 (de) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
CN101146799A (zh) * 2005-03-23 2008-03-19 贝林格尔·英格海姆国际有限公司 Cgrp拮抗剂、其制备方法以及其作为药物的用途
US7491717B2 (en) * 2005-03-23 2009-02-17 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102005038831A1 (de) * 2005-08-17 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1770087A1 (de) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1770086A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102006017827A1 (de) * 2006-04-13 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue kristalline Verbindungen
PE20080370A1 (es) * 2006-06-08 2008-06-13 Boehringer Ingelheim Int Derivados de quinazolinona como antagonistas de cgrp

Also Published As

Publication number Publication date
CL2007001663A1 (es) 2008-01-25
AU2007255395A1 (en) 2007-12-13
WO2007141284A3 (en) 2008-03-06
UY30398A1 (es) 2008-01-31
CL2007001662A1 (es) 2008-01-25
EA200802381A1 (ru) 2009-06-30
BRPI0712492A2 (pt) 2012-08-21
TW200815010A (en) 2008-04-01
KR20090021214A (ko) 2009-02-27
CA2654048A1 (en) 2007-12-13
IL195712A0 (en) 2009-09-01
MX2008015562A (es) 2008-12-17
ECSP089025A (es) 2009-01-30
CA2654047A1 (en) 2007-12-13
US20080139537A1 (en) 2008-06-12
WO2007141285A1 (en) 2007-12-13
US20080139591A1 (en) 2008-06-12
PE20080153A1 (es) 2008-04-14
EP2029234A1 (en) 2009-03-04
AR061272A1 (es) 2008-08-13
JP2009539800A (ja) 2009-11-19
PE20080370A1 (es) 2008-06-13
AR061271A1 (es) 2008-08-13
TW200808791A (en) 2008-02-16
EP2029233A2 (en) 2009-03-04
US7807666B2 (en) 2010-10-05
CN101500653A (zh) 2009-08-05
WO2007141284A2 (en) 2007-12-13
NO20085051L (no) 2008-12-19
JP2009539799A (ja) 2009-11-19

Similar Documents

Publication Publication Date Title
UY30399A1 (es) Uso de antagonistas de cgrp (a), sus enantinmeros, diasternmeros, mezclas y sales farmaccuticamente aceptables para preparar medicamentos, y composiciones que los contienen"
AR047992A1 (es) Diaminopirimidinas como antagonistas de p2x3 y p2x2/3
CL2012000925A1 (es) Compuestos derivados de tetrahidrociclohepta[b]piridinilo, antagonista del receptor de cgrp; composicion farmaceutica que lo comprende; y su uso en el tratamiento de migraña, cefalea, diabetes, cancer, entre otras.
SV2010003580A (es) Agonistas novedosos de los receptores de glucocorticoides
CR10356A (es) Derivados de 4-benzilphthalazinona 2-sustituidos como antagonistas de histamina h1 y h3
NI201100084A (es) Antagonistas del receptor de orexina de isonicotinamida.
UY31050A1 (es) Antagonistas de trpv1 y usos de los mismos
CO6400144A2 (es) Derivados aminoéster de alcaloides y composición medicinal de los mismos
PA8660401A1 (es) Derivados de triazol sustituidos como antagonistas de oxitocina
HN2008000646A (es) Antagonistas de los receptores 2 de dopamina de rapida disociacion
UY33238A (es) "Compuestos en calidad de antagonistas de bradiquinina-b1"
ECSP088283A (es) Compuestos de piridina 5- (fenilisoxazoliletoxi) -triazol- 3-ilo substituidos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
ES2570374T3 (es) Antagonistas del receptor opioide periférico y usos de los mismos
ECSP11011151A (es) Compuestos purina
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38
UY31048A1 (es) Nuevos compuestos de pirimidina y usos de los mismos
UY33655A (es) Co-cristales y sales de inhibidores de ccr30
PA8576101A1 (es) Difenilazetidinonas sustituidas en grupo acido, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
UY28765A1 (es) Compuestos de piperazina acetilínica y su uso como antagonistas del receptor de glutamato metabotrópico
UY30723A1 (es) Compuestos de biciclocarboxiamida sustituidos
DOP2006000202A (es) Derivados de carboxamida como antagonistas del receptor muscarinico
UY27851A1 (es) Difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
DOP2019000070A (es) Compuestos de aza–indazol para usar en lesiones de tendones y/o ligamentos
ECSP10010105A (es) Antagonistas de cgrp

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170627